ResearcherHarvard UniversityActive in the last 2 years
Hiromichi Ito
Matched on OpenAlex author ID A5111946706. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2023: 4 papers · 2024: none · 2025: none · 2026: 1 paper
Papers 5
- ASO Author Reflections: Beware the Collaterals: Vein Formation Signals Higher Surgical Risk in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18960-9↗
- Retraction notice to Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity [Surgery -September 2004, Pages… Co-author DOI 10.1016/j.surg.2023.01.009↗
- Retraction Note: CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. First author DOI 10.1038/s41388-023-02625-6↗
- Retraction Note: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. First author DOI 10.1038/s41388-023-02626-5↗
- Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005395↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mark S. Duxbury · 3 shared papers, 2023 · strength 0.71
- Paper Retraction notice to Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 … DOI 10.1016/j.surg.2023.01.009↗
- Paper Retraction Note: CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenoca… DOI 10.1038/s41388-023-02625-6↗
- Paper Retraction Note: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic a… DOI 10.1038/s41388-023-02626-5↗
- Stanley W. Ashley · 3 shared papers, 2023 · strength 0.71
- Paper Retraction notice to Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 … DOI 10.1016/j.surg.2023.01.009↗
- Paper Retraction Note: CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenoca… DOI 10.1038/s41388-023-02625-6↗
- Paper Retraction Note: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic a… DOI 10.1038/s41388-023-02626-5↗
- Edward E. Whang · 3 shared papers, 2023 · strength 0.71
- Paper Retraction notice to Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 … DOI 10.1016/j.surg.2023.01.009↗
- Paper Retraction Note: CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenoca… DOI 10.1038/s41388-023-02625-6↗
- Paper Retraction Note: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic a… DOI 10.1038/s41388-023-02626-5↗
- Yu Takahashi · 2 shared papers, 2023–2026 · strength 0.46
- Paper ASO Author Reflections: Beware the Collaterals: Vein Formation Signals Higher Surgical Risk in Pancreatic Ductal Adenoc… DOI 10.1245/s10434-025-18960-9↗
- Paper Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. DOI 10.1097/sla.0000000000005395↗
- Yosuke Inoue · 2 shared papers, 2023–2026 · strength 0.46
- Paper ASO Author Reflections: Beware the Collaterals: Vein Formation Signals Higher Surgical Risk in Pancreatic Ductal Adenoc… DOI 10.1245/s10434-025-18960-9↗
- Paper Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. DOI 10.1097/sla.0000000000005395↗
- Yoshihiro Ono · 2 shared papers, 2023–2026 · strength 0.46
- Paper ASO Author Reflections: Beware the Collaterals: Vein Formation Signals Higher Surgical Risk in Pancreatic Ductal Adenoc… DOI 10.1245/s10434-025-18960-9↗
- Paper Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. DOI 10.1097/sla.0000000000005395↗
- Atsushi Oba · 2 shared papers, 2023–2026 · strength 0.46
- Paper ASO Author Reflections: Beware the Collaterals: Vein Formation Signals Higher Surgical Risk in Pancreatic Ductal Adenoc… DOI 10.1245/s10434-025-18960-9↗
- Paper Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. DOI 10.1097/sla.0000000000005395↗
- Tatsunori Miyata · 1 shared paper, 2026 · strength 0.30
- Masaaki Iwatsuki · 1 shared paper, 2026 · strength 0.30
- Y. H. Andrew Wu · 1 shared paper, 2023 · strength 0.16
- Takashi Sasaki · 1 shared paper, 2023 · strength 0.16
- Masato Ozaka · 1 shared paper, 2023 · strength 0.16
- Kojiro Omiya · 1 shared paper, 2023 · strength 0.16
- Akio Saiura · 1 shared paper, 2023 · strength 0.16
- Naoki Sasahira · 1 shared paper, 2023 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.